Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Etsy Inc (ETSY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Etsy Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Etsy Inc trades at $76.72 (market cap $7.36B). The key difference: Etsy Inc is the larger of the two by market cap, and Etsy Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | ETSY | |
|---|---|---|
Market Cap | $4.49B | $7.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $79.66 |
52-Week Low | $20.06 | $44.05 |
Enterprise Value | $3.69B | $9.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ETSY trades at $77.59, up 0.81% today, with a bullish technical signal from moving averages and support at $74. The company reported three consecutive quarterly earnings beats, with Q1 2026 EPS of $0.89 beating expectations of $0.62 (Seeking Alpha, 2026-05-29). Revenue for 2025 was $2.88B, though net income declined to $163M. Analyst consensus is a Buy with a $70.79 price target, and recent news highlights growth in AI seller tools and buyer recovery momentum.
ETSY shows potential with strong profitability margins and positive cash flow trends, but faces risks from high debt and competitive pressures. The stock's valuation multiples like P/E of 28.76 suggest moderate premium, while institutional sentiment remains cautiously optimistic amid execution challenges in sustaining growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →
